Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma

In this editorial, the generalizability of trial results to the geriatric population is discussed. Specifically, the results from a recent observational study are compared with results from the SHARP trial, and recommendations are made for bridging the gap between efficacy and effectiveness in clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Nipp, Ryan, Goyal, Lipika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189629/
https://www.ncbi.nlm.nih.gov/pubmed/27807300
http://dx.doi.org/10.1634/theoncologist.2016-0349
_version_ 1782487278143143936
author Nipp, Ryan
Goyal, Lipika
author_facet Nipp, Ryan
Goyal, Lipika
author_sort Nipp, Ryan
collection PubMed
description In this editorial, the generalizability of trial results to the geriatric population is discussed. Specifically, the results from a recent observational study are compared with results from the SHARP trial, and recommendations are made for bridging the gap between efficacy and effectiveness in clinical research, particularly with regard to older patients.
format Online
Article
Text
id pubmed-5189629
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-51896292016-12-28 Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma Nipp, Ryan Goyal, Lipika Oncologist Commentary In this editorial, the generalizability of trial results to the geriatric population is discussed. Specifically, the results from a recent observational study are compared with results from the SHARP trial, and recommendations are made for bridging the gap between efficacy and effectiveness in clinical research, particularly with regard to older patients. AlphaMed Press 2016-11 2016-11-02 /pmc/articles/PMC5189629/ /pubmed/27807300 http://dx.doi.org/10.1634/theoncologist.2016-0349 Text en ©AlphaMed Press
spellingShingle Commentary
Nipp, Ryan
Goyal, Lipika
Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma
title Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma
title_full Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma
title_fullStr Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma
title_full_unstemmed Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma
title_short Bridging the Gap Between Sorafinib Efficacy and Effectiveness in Advanced Hepatocellular Carcinoma
title_sort bridging the gap between sorafinib efficacy and effectiveness in advanced hepatocellular carcinoma
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189629/
https://www.ncbi.nlm.nih.gov/pubmed/27807300
http://dx.doi.org/10.1634/theoncologist.2016-0349
work_keys_str_mv AT nippryan bridgingthegapbetweensorafinibefficacyandeffectivenessinadvancedhepatocellularcarcinoma
AT goyallipika bridgingthegapbetweensorafinibefficacyandeffectivenessinadvancedhepatocellularcarcinoma

Ejemplares similares